GuidelineAnnals of internal medicine2007
Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians.
Guideline in Annals of internal medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02613897 (A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy), which is not on this map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Do clinical standards for diabetes care address excess risk for hypoglycemia in vulnerable patients? A systematic review.Health services research · 2013Pooled it
- Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.Diabetes care · 2011Guideline
- The systematic guideline review: method, rationale, and test on chronic heart failure.BMC health services research · 2009Pooled it
- Efficacy of a language-concordant health coaching intervention for latinx with diabetes.Patient education and counseling · 2022Trial
- Improved sleep quality in older adults with insomnia reduces biomarkers of disease risk: pilot results from a randomized controlled comparative efficacy trial.Psychoneuroendocrinology · 2015Trial
- Prevalence of Hypertension and Its Associated Factors Among Patients with Type 2 Diabetes in Southern Afghanistan: A Multi-Center Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Prognostic model of in-hospital ischemic stroke mortality based on an electronic health record cohort in Indonesia.PloS one · 2024Observational
- Health-Related Quality of Life Among Type 2 Diabetes Mellitus Patients Using the 36-ItemDiabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.Diabetes care · 2023Review
- Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus.Clinical chemistry · 2023Article
- Development and Validation of a Risk Nomogram Model for Predicting Constipation in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in U.S. Adults.Diabetes care · 2022Article
- Bayesian profiling multiple imputation for missing hemoglobin values in electronic health records.The annals of applied statistics · 2020Article
- Citizenship and health insurance status predict glycemic management: NHANES data 2007-2016.Preventive medicine · 2020Article
- Burden of Uncontrolled Hyperglycemia and Its Association with Patients Characteristics and Socioeconomic Status in Philadelphia, USA.Health equity · 2020Article
- Factors that Correlate with Poor Glycemic Control in Type 2 Diabetes Mellitus Patients with Complications.Osong public health and research perspectives · 2018Article
- Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?Annals of translational medicine · 2018Article
- Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses.Journal of health economics and outcomes research · 2018Article
- Article
- The physician's experience of changing clinical practice: a struggle to unlearn.Implementation science : IS · 2017Article
Corrections and comments
- Commented on by
- Commented on by
- SummaryForPatientsIn
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This guidance statement is derived from other organizations' guidelines and is based on an evaluation of the strengths and weaknesses of the available guidelines. We used the Appraisal of Guidelines, Research and Evaluation in Europe (AGREE) appraisal instrument to evaluate the guidelines from various organizations. On the basis of the review of the available guidelines, we recommend: STATEMENT 1: To prevent microvascular complications of diabetes, the goal for glycemic control should be as low as is feasible without undue risk for adverse events or an unacceptable burden on patients. Treatment goals should be based on a discussion of the benefits and harms of specific levels of glycemic control with the patient. A hemoglobin A1c level less than 7% based on individualized assessment is a reasonable goal for many but not all patients. STATEMENT 2: The goal for hemoglobin A1c level should be based on individualized assessment of risk for complications from diabetes, comorbidity, life expectancy, and patient preferences. STATEMENT 3: We recommend further research to assess the optimal level of glycemic control, particularly in the presence of comorbid conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.